Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0000950170-25-102964
Filing Date
2025-08-05
Accepted
2025-08-05 16:00:08
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 11245
2 EX-99.A ck0000000000-ex99_a.pdf EX-99.A 83485
  Complete submission text file 0000950170-25-102964.txt   128299
Mailing Address SUITE 400, 2440 RESEARCH BLVD ROCKVILLE MD 20850
Business Address SUITE 400, 2440 RESEARCH BLVD ROCKVILLE MD 20850 (301) 670 2800
I-Mab (Subject) CIK: 0001778016 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-91674 | Film No.: 251184696
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address SUITE 6601-6606, PLAZA 66, TOWER 1 1266 WEST NANJING ROAD SHANGHAI China
Business Address SUITE 6601-6606, PLAZA 66, TOWER 1 1266 WEST NANJING ROAD SHANGHAI China 862180125755
Everest Medicines Ltd (Filed by) CIK: 0001783937 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)